Organogenesis (NASDAQ:ORGO) Director Glenn Nussdorf Purchases 251,001 Shares

Organogenesis (NASDAQ:ORGO) Director Glenn Nussdorf bought 251,001 shares of the stock in a transaction dated Wednesday, May 14th. The shares were acquired at an average price of $3.09 per share, for a total transaction of $775,593.09. Following the completion of the transaction, the director owned 251,001 shares of the company’s stock, valued at approximately $775,593.09. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Organogenesis Price Performance

Shares of NASDAQ:ORGO opened at $4.00 on Tuesday. The stock has a market cap of $507.44 million, a P/E ratio of -28.57 and a beta of 1.68. The firm has a fifty day moving average price of $4.48 and a 200 day moving average price of $4.19. Organogenesis has a 1-year low of $2.61 and a 1-year high of $6.71.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.08). Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. The business had revenue of $101.01 million during the quarter, compared to analyst estimates of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. Sell-side analysts expect that Organogenesis will post -0.07 EPS for the current fiscal year.

Institutional Trading of Organogenesis

Hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC grew its holdings in Organogenesis by 10.8% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company’s stock worth $187,000 after acquiring an additional 4,239 shares during the period. Cerity Partners LLC grew its stake in shares of Organogenesis by 48.2% during the 1st quarter. Cerity Partners LLC now owns 74,880 shares of the company’s stock worth $323,000 after purchasing an additional 24,362 shares during the period. CWM LLC grew its stake in shares of Organogenesis by 8.9% during the 1st quarter. CWM LLC now owns 63,894 shares of the company’s stock worth $276,000 after purchasing an additional 5,239 shares during the period. Victory Capital Management Inc. purchased a new position in shares of Organogenesis in the 1st quarter valued at about $67,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Organogenesis in the first quarter valued at about $631,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have commented on the company. BTIG Research reaffirmed a “buy” rating and set a $7.00 price objective on shares of Organogenesis in a research note on Friday, September 26th. Cantor Fitzgerald upped their price target on Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a research note on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Organogenesis in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Organogenesis has a consensus rating of “Hold” and an average price target of $7.33.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.